

SetPoint Medical Presents Positive Results In Ongoing Crohn's Disease Study

– Presentation at Innovations in Gastroenterology Symposium in Tel Aviv –

Valencia, CA and Tel Aviv, Israel – January 4, 2017 – [SetPoint Medical](#), a biomedical technology company developing a bioelectronic therapy for inflammatory diseases, presented positive results showing 6 of 8 patients reached the primary endpoint with significant improvement in Crohn's symptoms. The results are from an ongoing study modulating the inflammatory reflex to treat Crohn's Disease (CD), a debilitating disease caused by inflammation in the digestive tract. The data were presented in an oral presentation at the Innovations in Gastroenterology symposium in Tel Aviv.

The open-label pilot study is being conducted at five centers in Europe, including patients with moderately-to-severely active Crohn's despite treatment with a tumor necrosis factor (TNF) antagonist drug. The trial uses an implanted device to deliver digital doses of electricity, stimulating the vagus nerve with timed electrical pulses, activating the body's natural [Inflammatory Reflex](#) to produce a systemic anti-inflammatory effect.

"We are very encouraged by the positive results from our ongoing trial in Crohn's Disease, and we are evaluating a new cohort of patients as the study continues" said Yaakov Levine, Director of Applied Research at SetPoint Medical. "Patients living with Crohn's need more treatment options, and bioelectronic medicine shows promise as a new approach for Crohn's, rheumatoid arthritis and other inflammatory diseases."

In this study, eight patients with severe Crohn's Disease not responsive to TNF antagonists received an implant on the vagus nerve in their neck to deliver electrical doses to the vagus nerve.

Improvement was assessed at the sixteen-week mark using the primary endpoint for the study – a change from baseline to week 16 in the Crohn's Disease Activity Index (CDAI), a tool used to quantify the symptoms of patients with the disease. Severe Crohn's is defined by a CDAI greater than 450, and remission is defined as a CDAI below 150.

At the primary end point, the CDAI scores of six of the eight patients in the study were reduced by 70 points or more, and CDAI remission and endoscopic remission was achieved in three patients.

These results were previously presented at United European Gastroenterology Week (UEGW) in Vienna, in October 2016.

SetPoint is developing a [novel proprietary bioelectronic medicine platform](#) to treat a variety of inflammation-mediated autoimmune diseases by activating the body's natural [Inflammatory Reflex](#) to produce a systemic anti-inflammatory effect. The emerging field of bioelectronic medicine aims to address unmet patient needs utilizing digital dose delivery to modulate disease pathways historically treated with drugs.

About SetPoint Medical

[SetPoint Medical](#) is a privately held biomedical technology company dedicated to treating patients with debilitating inflammatory diseases using bioelectronic therapy. SetPoint's approach is intended to offer patients and providers an [alternative](#) for the treatment of rheumatoid arthritis (RA) and other chronic inflammatory diseases with less risk and cost than drug therapy. SetPoint's therapy is also being evaluated in an open-label clinical study for Crohn's Disease.

SetPoint is developing a novel bioelectronic medicine platform consisting of an implantable miniature neuromodulation device and iPad prescription pad application. The implantable device stimulates the vagus nerve to activate the body's natural Inflammatory Reflex, which is intended to produce a potent systemic anti-inflammatory effect. The company has published positive results from a first-in-human open-label proof-of-concept trial in rheumatoid arthritis in *Proceedings of the National Academy of Sciences* (PNAS) and presented positive results at the American College of Rheumatology meeting. Current investors in the company include Morgenthaler Ventures, Flare Capital Partners, Topspin Partners, Medtronic, GlaxoSmithKline's Action Potential Venture Capital Limited and Boston Scientific. For more information, visit www.setpointmedical.com.

#

Media Contact:

Kathryn Morris

O: 845-635-9828

M: 914-204-6412

kathryn@brightpointny.com